Ablynx

Technologiepark 21

9052 Zwijnaarde

BE

Ablynx

Foundation date

2001

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

Upcoming events

Latest news

  • miDiagnostics to pilot innovative, fast COVID-19 PCR testing solutions at Brussels Airport

    Friday October 15th 2021

  • VIB celebrates 25 years of groundbreaking research

    Wednesday October 13th 2021

  • Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

    Wednesday October 13th 2021